EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Hepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome

Scott L Friedman

Diabetes & Metabolism Journal · 2024

DOI: 10.4093/dmj.2023.0240 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes & Metabolism Journal, 2024. Verfasst von Scott L Friedman. Beteiligte Einrichtung: Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Metabolic Syndrome, Diabetes Mellitus, Type 2, Liver Neoplasms. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS, National Institute of Diabetes, Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metabolic dysfunction-associated steatotic (fatty) liver disease (MASLD), previously termed non-alcoholic fatty liver disease, is a worldwide epidemic that can lead to hepatic inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). The disease is typically a component of the metabolic syndrome that accompanies obesity, and is often overlooked because the liver manifestations are clinically silent until late-stage disease is present (i.e., cirrhosis). Moreover, Asian populations, including Koreans, have a higher fraction of patients who are lean, yet their illness has the same prognosis or worse than those who are obese. Nonetheless, ongoing injury can lead to hepatic inflammation and ballooning of hepatocytes as classic features. Over time, fibrosis develops following activation of hepatic stellate cells, the liver’s main fibrogenic cell type. The disease is usually more advanced in patients with type 2 diabetes mellitus, indicating that all diabetic patients should be screened for liver disease. Although there has been substantial progress in clarifying pathways of injury and fibrosis, there no approved therapies yet, but current research seeks to uncover the pathways driving hepatic inflammation and fibrosis, in hopes of identifying new therapeutic targets. Emerging molecular methods, especially single cell sequencing technologies, are revolutionizing our ability to clarify mechanisms underlying MASLD-associated fibrosis and HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularMetabolic SyndromeDiabetes Mellitus, Type 2Liver NeoplasmsNon-alcoholic Fatty Liver DiseaseHumansLiver CirrhosisObesityInflammation

Stichwörter der Autor:innen

Carcinoma, hepatocellularDiabetes mellitus, type 2Extracellular matrixFibrosisHepatic stellate cellsLiver diseasesLiver neoplasms

Autor:innen und Institutionen

  • Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Förderung

  • NIDDK NIH HHS
  • National Institute of Diabetes, Digestive and Kidney Diseases

Zitieren

APA

Friedman, S. L. (2024). Hepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome. Diabetes & Metabolism Journal. https://doi.org/10.4093/dmj.2023.0240

Vancouver

Friedman SL. Hepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome. Diabetes & Metabolism Journal. 2024. doi:10.4093/dmj.2023.0240

BibTeX
@article{Friedman2024,
  author = {Friedman, Scott L},
  title = {Hepatic Fibrosis and Cancer: The Silent Threats of Metabolic Syndrome},
  journal = {Diabetes & Metabolism Journal},
  year = {2024},
  doi = {10.4093/dmj.2023.0240}
}
Kostenlos starten →